RESUMEN
Measles in persons with secondary vaccination failure (SVF) may be less infectious than cases in unvaccinated persons. Our systematic review aimed to assess transmission risk for measles after SVF. We searched PubMed, Embase, and Web of Science databases from their inception dates. Inclusion criteria were articles describing persons who were exposed to measles-infected persons who had experienced SVF. Across the included 14 studies, >3,030 persons were exposed to measles virus from SVF cases, of whom 180 were susceptible, indicating secondary attack rates of 0%-6.25%. We identified 109 cases of SVF from the studies; 10.09% (n = 11) of case-patients transmitted the virus, resulting in 23 further cases and yielding an effective reproduction number of 0.063 (95% CI 0.0-0.5). These findings suggest a remarkably low attack rate for SVF measles cases, suggesting that, In outbreak situations, public health management of unvaccinated persons could be prioritized over persons with SVF.
Asunto(s)
Vacuna Antisarampión , Virus del Sarampión , Sarampión , Humanos , Sarampión/transmisión , Sarampión/prevención & control , Sarampión/epidemiología , Vacuna Antisarampión/administración & dosificación , Virus del Sarampión/inmunología , Inmunización Secundaria , Brotes de Enfermedades , Insuficiencia del Tratamiento , VacunaciónRESUMEN
Although neutralizing antibody is an established correlate of protection for measles, T cell-mediated responses play at least two critical roles in immunity to measles: first, through provision of 'help' enabling robust humoral immune responses; and second, through clearance of measles virus-infected cells. Previously, we identified 13 measles-derived peptides that bound to human leukocyte antigen (HLA) molecules in Priess cells infected with measles virus. In this study, we evaluated the immunogenicity of these peptides in a transgenic mouse model. Our results demonstrated that these peptides induced Th1-biased immune responses at varying levels. Of the 13 peptides, the top four immunogenic peptides were further selected for a viral challenge study in mice. A vaccine based on a combination of these four peptides reduced morbidity and weight loss after viral challenge compared to placebo. Our results emphasize the potential of T cell-mediated, peptide-based vaccines against measles.
Asunto(s)
Modelos Animales de Enfermedad , Vacuna Antisarampión , Virus del Sarampión , Sarampión , Ratones Transgénicos , Vacunas de Subunidad , Animales , Sarampión/prevención & control , Sarampión/inmunología , Ratones , Vacuna Antisarampión/inmunología , Virus del Sarampión/inmunología , Humanos , Vacunas de Subunidad/inmunología , Proyectos Piloto , Anticuerpos Antivirales/inmunología , Péptidos/inmunología , Péptidos/química , Anticuerpos Neutralizantes/inmunología , Femenino , Células TH1/inmunología , Inmunogenicidad VacunalRESUMEN
A woman in her 40s known to have systemic lupus erythematosus presented with a maculopapular rash on her face, neck and chest following measles exposure. She had received a single-dose measles vaccine as a child in the 1970s and was therefore presumed to be immune, and thus not infectious. As a result, she was initially managed in an open bay. Measles virus IgM antibody in serum was undetectable; however, measles virus RNA was subsequently detected in throat swab by PCR, which is consistent with current infection. Measles is one of the most transmissible diseases in the world and cases are rising both in the UK and globally. Our case and literature review highlight the risk of vaccine failure in measles, especially in people who have not received two doses of the measles, mumps and rubella vaccine. It also highlights the challenges in diagnosing measles in previously vaccinated individuals.
Asunto(s)
Sarampión , Humanos , Sarampión/prevención & control , Sarampión/diagnóstico , Femenino , Vacuna Antisarampión , Adulto , Virus del Sarampión/inmunología , Virus del Sarampión/aislamiento & purificación , Vacuna contra el Sarampión-Parotiditis-Rubéola , Lupus Eritematoso Sistémico/complicaciones , Lupus Eritematoso Sistémico/inmunología , Vacunación , Persona de Mediana Edad , Anticuerpos Antivirales/sangre , Inmunoglobulina M/sangreRESUMEN
Measles is a highly transmissible systemic viral infection associated with substantial mortality primarily due to secondary infections. Measles induces lifelong immunity to reinfection but loss of immunity to other pathogens. An attenuated live virus vaccine is highly effective, but lapses in delivery have resulted in increasing cases worldwide. Although the primary cause of failure to control measles is failure to vaccinate, waning vaccine-induced immunity and the possible emergence of more virulent virus strains may also contribute.
Asunto(s)
Vacuna Antisarampión , Virus del Sarampión , Sarampión , Sarampión/prevención & control , Sarampión/inmunología , Sarampión/virología , Humanos , Vacuna Antisarampión/inmunología , Virus del Sarampión/inmunología , Vacunación , Vacunas Atenuadas/inmunologíaRESUMEN
Introduction. At the end of 2019 and the year before, there was a significant spread of measles in the World Health Organization (WHO) European Region.Gap statement. Among the countries that reported, a measles outbreak was Bosnia and Herzegovina (BiH).Aim. To describe the measles outbreak in BiH (an entity of the Federation of BiH, FBiH) in 2019.Methodology. Confirmatory IgM serology, measles nucleic acid detection by real-time RT-PCR and virus genotyping were done in the WHO-accredited laboratory for measles and rubella at the Clinical Center of the University of Sarajevo, Unit for Clinical Microbiology. Genotype was determined in all measles-RNA-positive cases by sequence analysis of the 450 nt fragment coding the C-terminal of measles virus nucleoprotein (N).Results. From 1 January to 31 December 2019, 1332 measles cases were reported, with the peak observed in April 2019 (413/1332, 31.01â%). Sarajevo Canton had the highest incidence, number of cases and percentage (206.4; 868/1332; 65.17â%) of measles cases. Around four-fifths of infected persons were unvaccinated (1086/1332, 81.53â%), while 4.58â% of the patients (61/1332) were immunized with one dose of measles-containing vaccine. The highest proportion of cases was found in children 0-6 years of age (738/1332, 55.41â%). Measles IgM positivity was determined in 75.88â% (346/456), while virus RNA was detected in 82.46â% (47/57) of the swab samples. All measles virus sequences belonged to genotype B3. SNP (position 216: C=>T) was detected in 1 of the 40 sequences obtained during this outbreak.Conclusion. Due to suboptimal immunization coverage, BiH belongs to countries at a high risk for measles outbreaks. Post-COVID-19 (coronavirus disease 2019) pandemic, targeted and tailored strategies are required to ensure routine vaccination demand and acceptance and broad partner and stakeholder group participation.
Asunto(s)
COVID-19 , Brotes de Enfermedades , Genotipo , Virus del Sarampión , Sarampión , Humanos , Sarampión/epidemiología , Sarampión/virología , Sarampión/prevención & control , Virus del Sarampión/genética , Virus del Sarampión/aislamiento & purificación , Virus del Sarampión/clasificación , Virus del Sarampión/inmunología , Niño , Masculino , Adulto , Preescolar , Adolescente , Femenino , Adulto Joven , Lactante , COVID-19/epidemiología , COVID-19/prevención & control , Bosnia y Herzegovina/epidemiología , Persona de Mediana Edad , Inmunoglobulina M/sangre , ARN Viral/genética , SARS-CoV-2/genética , SARS-CoV-2/inmunología , SARS-CoV-2/aislamiento & purificación , Vacuna Antisarampión/administración & dosificación , Anticuerpos Antivirales/sangreRESUMEN
The seropositivity of measles antibodies among 261 autologous stem cell transplant recipients (ASCTs) in Korea, assessed approximately 1-2 years after transplant (median, 11 months; interquartile range, 9-14), was significantly lower than age- and sex-matched control healthcare workers (83.1% [217/261] vs. 90.3% [539/597], P = 0.002). The findings underscore the vulnerability of adult ASCT recipients to measles. Clinicians should prioritize testing for measles IgG after ASCT and consider vaccination for ASCT recipients who remain seronegative 2 years after ASCT.
Asunto(s)
Anticuerpos Antivirales , Trasplante de Células Madre Hematopoyéticas , Inmunoglobulina G , Sarampión , Trasplante Autólogo , Humanos , Trasplante de Células Madre Hematopoyéticas/efectos adversos , Sarampión/inmunología , Sarampión/prevención & control , República de Corea , Masculino , Femenino , Adulto , Anticuerpos Antivirales/sangre , Persona de Mediana Edad , Inmunoglobulina G/sangre , Vacuna Antisarampión/inmunología , Virus del Sarampión/inmunologíaRESUMEN
As the new SARS-CoV-2 Omicron variants and subvariants emerge, there is an urgency to develop intranasal, broadly protective vaccines. Here, we developed highly efficacious, intranasal trivalent SARS-CoV-2 vaccine candidates (TVC) based on three components of the MMR vaccine: measles virus (MeV), mumps virus (MuV) Jeryl Lynn (JL1) strain, and MuV JL2 strain. Specifically, MeV, MuV-JL1, and MuV-JL2 vaccine strains, each expressing prefusion spike (preS-6P) from a different variant of concern (VoC), were combined to generate TVCs. Intranasal immunization of IFNAR1-/- mice and female hamsters with TVCs generated high levels of S-specific serum IgG antibodies, broad neutralizing antibodies, and mucosal IgA antibodies as well as tissue-resident memory T cells in the lungs. The immunized female hamsters were protected from challenge with SARS-CoV-2 original WA1, B.1.617.2, and B.1.1.529 strains. The preexisting MeV and MuV immunity does not significantly interfere with the efficacy of TVC. Thus, the trivalent platform is a promising next-generation SARS-CoV-2 vaccine candidate.
Asunto(s)
Administración Intranasal , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Vacunas contra la COVID-19 , COVID-19 , SARS-CoV-2 , Glicoproteína de la Espiga del Coronavirus , Animales , Glicoproteína de la Espiga del Coronavirus/inmunología , Glicoproteína de la Espiga del Coronavirus/genética , Femenino , SARS-CoV-2/inmunología , SARS-CoV-2/genética , COVID-19/prevención & control , COVID-19/inmunología , COVID-19/virología , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/sangre , Anticuerpos Neutralizantes/inmunología , Anticuerpos Neutralizantes/sangre , Ratones , Vacunas contra la COVID-19/inmunología , Vacunas contra la COVID-19/administración & dosificación , Cricetinae , Humanos , Vacuna contra el Sarampión-Parotiditis-Rubéola/inmunología , Vacuna contra el Sarampión-Parotiditis-Rubéola/administración & dosificación , Virus del Sarampión/inmunología , Virus del Sarampión/genética , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Virus de la Parotiditis/inmunología , Virus de la Parotiditis/genética , Ratones Noqueados , Mesocricetus , Inmunoglobulina A/inmunología , Inmunoglobulina A/sangreAsunto(s)
Anticuerpos Antivirales , Sarampión , Humanos , Femenino , Sarampión/inmunología , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/sangre , Masculino , Vacuna Antisarampión/inmunología , Vacuna Antisarampión/administración & dosificación , Embarazo , Inmunidad Materno-Adquirida/inmunología , Factores Sexuales , Virus del Sarampión/inmunologíaRESUMEN
An intermediate virus-cell fusion step is revealed by an antibody with therapeutic potential.
Asunto(s)
Anticuerpos Monoclonales , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Virus del Sarampión , Sarampión , Internalización del Virus , Animales , Humanos , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales/inmunología , Anticuerpos Neutralizantes/inmunología , Anticuerpos Antivirales/inmunología , Sarampión/prevención & control , Virus del Sarampión/inmunología , Virus del Sarampión/fisiología , Internalización del Virus/efectos de los fármacosRESUMEN
Measles virus (MeV) presents a public health threat that is escalating as vaccine coverage in the general population declines and as populations of immunocompromised individuals, who cannot be vaccinated, increase. There are no approved therapeutics for MeV. Neutralizing antibodies targeting viral fusion are one potential therapeutic approach but have not yet been structurally characterized or advanced to clinical use. We present cryo-electron microscopy (cryo-EM) structures of prefusion F alone [2.1-angstrom (Å) resolution], F complexed with a fusion-inhibitory peptide (2.3-Å resolution), F complexed with the neutralizing and protective monoclonal antibody (mAb) 77 (2.6-Å resolution), and an additional structure of postfusion F (2.7-Å resolution). In vitro assays and examination of additional EM classes show that mAb 77 binds prefusion F, arrests F in an intermediate state, and prevents transition to the postfusion conformation. These structures shed light on antibody-mediated neutralization that involves arrest of fusion proteins in an intermediate state.
Asunto(s)
Anticuerpos Monoclonales , Anticuerpos Neutralizantes , Anticuerpos Antivirales , Microscopía por Crioelectrón , Virus del Sarampión , Proteínas Virales de Fusión , Anticuerpos Neutralizantes/inmunología , Anticuerpos Neutralizantes/química , Virus del Sarampión/inmunología , Virus del Sarampión/química , Proteínas Virales de Fusión/inmunología , Proteínas Virales de Fusión/química , Anticuerpos Monoclonales/inmunología , Anticuerpos Monoclonales/química , Anticuerpos Antivirales/inmunología , Anticuerpos Antivirales/química , Humanos , Conformación ProteicaRESUMEN
How viral infections develop can change based on the number of viruses initially entering the body. The understanding of the impacts of infection doses remains incomplete, in part due to challenging constraints, and a lack of research. Gaining more insights is crucial regarding the measles virus (MV). The higher the MV infection dose, the earlier the peak of acute viremia, but the magnitude of the peak viremia remains almost constant. Measles is highly contagious, causes immunosuppression such as lymphopenia, and contributes substantially to childhood morbidity and mortality. This work investigated mechanisms underlying the observed wild-type measles infection dose responses in cynomolgus monkeys. We fitted longitudinal data on viremia using maximum likelihood estimation, and used the Akaike Information Criterion (AIC) to evaluate relevant biological hypotheses and their respective model parameterizations. The lowest AIC indicates a linear relationship between the infection dose, the initial viral load, and the initial number of activated MV-specific T cells. Early peak viremia is associated with high initial number of activated MV-specific T cells. Thus, when MV infection dose increases, the initial viremia and associated immune cell stimulation increase, and reduce the time it takes for T cell killing to be sufficient, thereby allowing dose-independent peaks for viremia, MV-specific T cells, and lymphocyte depletion. Together, these results suggest that the development of measles depends on virus-host interactions at the start and the efficiency of viral control by cellular immunity. These relationships are additional motivations for prevention, vaccination, and early treatment for measles.
Asunto(s)
Macaca fascicularis , Conceptos Matemáticos , Virus del Sarampión , Sarampión , Carga Viral , Viremia , Sarampión/inmunología , Sarampión/transmisión , Sarampión/prevención & control , Sarampión/virología , Sarampión/epidemiología , Animales , Viremia/inmunología , Viremia/virología , Virus del Sarampión/inmunología , Virus del Sarampión/patogenicidad , Virus del Sarampión/fisiología , Funciones de Verosimilitud , Humanos , Modelos Inmunológicos , Modelos Biológicos , Linfocitos T/inmunología , Activación de LinfocitosRESUMEN
The plaque reduction neutralization test (PRNT) and the enzyme-linked immunosorbent assay (ELISA) are both widely used to assess immunity to infectious diseases such as measles, but they use two different measurement principles: ELISA measures the ability of antibodies to bind to virus components, while the PRNT detects the aptitude of antibodies to prevent the infection of a susceptible cell. As a result, detection of measles virus (MV) neutralizing antibodies is the gold standard for assessing immunity to measles. However, the assay is laborious and requires experience and excellent technical skills. In addition, the result is only available after several days. Therefore, the classical PRNT is not suitable for high-throughput testing. By using an immunocolorimetric assay (ICA) to detect MV-infected cells, the standard PRNT has been developed into a focus reduction neutralization test (FRNT). This assay is faster and has improved specificity. The FRNT described here is extremely useful when immunity to measles virus needs to be assessed in patients with a specific medical condition, such as immunocompromised individuals in whom presumed residual immunity needs to be assessed. The FRNT is not generally recommended for use with large numbers of specimens, such as in a seroprevalence study.
Asunto(s)
Anticuerpos Neutralizantes , Anticuerpos Antivirales , Virus del Sarampión , Sarampión , Pruebas de Neutralización , Pruebas de Neutralización/métodos , Virus del Sarampión/inmunología , Sarampión/inmunología , Sarampión/diagnóstico , Sarampión/virología , Humanos , Anticuerpos Neutralizantes/inmunología , Anticuerpos Neutralizantes/sangre , Anticuerpos Antivirales/inmunología , Chlorocebus aethiops , Animales , Células Vero , Ensayo de Placa Viral/métodos , Ensayo de Inmunoadsorción Enzimática/métodosRESUMEN
Measles IgG avidity assays determine the overall strength of molecular binding between measles-specific IgG antibodies and measles virus antigens. Avidity results can distinguish recent from distant measles virus infections. Individuals who are immunologically naïve to measles virus develop low-avidity antibodies upon measles virus infection or first-time vaccination. Within 4-6 months, antibodies mature to high avidity. Measles avidity assays are most useful in the context of measles elimination. In such settings, avidity and epidemiological and clinical information are used to classify measles breakthrough infections for control and surveillance purposes and to assist in case confirmation when other laboratory results are inconclusive or nonexistent. We present a highly accurate end-titer measles avidity assay that delivers results based on IgG quality (avidity) that are independent of IgG concentration.
Asunto(s)
Anticuerpos Antivirales , Afinidad de Anticuerpos , Inmunoglobulina G , Virus del Sarampión , Sarampión , Afinidad de Anticuerpos/inmunología , Inmunoglobulina G/inmunología , Humanos , Anticuerpos Antivirales/inmunología , Virus del Sarampión/inmunología , Sarampión/inmunología , Sarampión/virología , Antígenos Virales/inmunología , Ensayo de Inmunoadsorción Enzimática/métodosRESUMEN
There is increasing interest in evaluating antibody responses to multiple antigen targets in a single assay. Immunity to measles and rubella are often evaluated together because immunity is provided through combined vaccines and because routine immunization efforts and surveillance for measles and rubella pathogens are combined in many countries. The multiplex bead assay (MBA) also known as the multiplex immunoassay (MIA) described here combines the measurement of measles- and rubella-specific IgG antibodies in serum quantitatively according to international serum standards and has been successfully utilized in integrated serological surveillance.
Asunto(s)
Anticuerpos Antivirales , Inmunoglobulina G , Sarampión , Rubéola (Sarampión Alemán) , Rubéola (Sarampión Alemán)/inmunología , Rubéola (Sarampión Alemán)/epidemiología , Rubéola (Sarampión Alemán)/diagnóstico , Rubéola (Sarampión Alemán)/sangre , Sarampión/inmunología , Sarampión/epidemiología , Sarampión/sangre , Sarampión/diagnóstico , Humanos , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Inmunoglobulina G/sangre , Inmunoglobulina G/inmunología , Inmunoensayo/métodos , Virus de la Rubéola/inmunología , Virus del Sarampión/inmunología , Pruebas Serológicas/métodosRESUMEN
Measles remains a major threat to human health despite widespread vaccination. While we know that maternal antibodies can impair vaccine-induced immunity, the relative contributions of pre-existing immunity levels, maternal and infant characteristics on vaccine responses remain unclear, hampering evidence-based vaccination policy development. Here we combine serological data from 1,505 individuals (aged 0-12 years) in a mother-infant cohort and in a child cohort with empirical models to reconstruct antibody trajectories from birth. We show that while highly heterogeneous across a population, measles antibody evolution is strongly predictive from birth at the individual level, including following vaccination. Further, we find that caesarean section births were linked with 2.56 (95% confidence interval: 1.06-6.37) increased odds of primary vaccine failure, highlighting the long-term immunological consequences of birth route. Finally, we use our new understanding of antibody evolution to critically assess the population-level consequences of different vaccination schedules, the results of which will allow country-level evaluations of vaccine policy.
Asunto(s)
Anticuerpos Antivirales , Vacuna Antisarampión , Sarampión , Vacunación , Humanos , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Vacuna Antisarampión/inmunología , Vacuna Antisarampión/administración & dosificación , Sarampión/inmunología , Sarampión/prevención & control , Femenino , Lactante , Preescolar , Recién Nacido , Niño , Masculino , Inmunidad Materno-Adquirida/inmunología , Adulto , Estudios de Cohortes , Virus del Sarampión/inmunología , EmbarazoAsunto(s)
Anticuerpos Antivirales , Recien Nacido Prematuro , Sarampión , Humanos , Anticuerpos Antivirales/sangre , Anticuerpos Antivirales/inmunología , Sarampión/inmunología , Sarampión/epidemiología , Sarampión/prevención & control , Recien Nacido Prematuro/inmunología , Recién Nacido , Vacuna Antisarampión/inmunología , Vacuna Antisarampión/administración & dosificación , Virus del Sarampión/inmunología , LactanteRESUMEN
A measles outbreak with 51 cases occurred in the canton of Vaud, Switzerland, between January and March 2024. The outbreak was triggered by an imported case, and 37 (72.5%) subsequent cases were previously vaccinated individuals. Epidemiological investigations showed that vaccinated measles cases were symptomatic and infectious. In a highly vaccinated population, it is important to raise awareness among healthcare professionals to suspect and test for measles virus when an outbreak is declared, irrespective of the vaccination status of the patients.
Asunto(s)
Brotes de Enfermedades , Vacuna Antisarampión , Virus del Sarampión , Sarampión , Vacunación , Humanos , Sarampión/prevención & control , Sarampión/epidemiología , Suiza/epidemiología , Brotes de Enfermedades/prevención & control , Vacuna Antisarampión/administración & dosificación , Vacunación/estadística & datos numéricos , Masculino , Femenino , Adulto , Adolescente , Niño , Virus del Sarampión/inmunología , Virus del Sarampión/aislamiento & purificación , Preescolar , Adulto Joven , LactanteRESUMEN
BACKGROUND: Measles has been a significant public health concern in Pakistan, especially in the Khyber Pakhtunkhwa (KPK) province, where sporadic and silent epidemics continue to challenge existing control measures. This study aimed to estimate the prevalence and investigate the molecular epidemiology of the measles virus (MeV) in KPK and explore the vaccination status among the suspected individuals. METHODS: A cross-sectional study was conducted between February and October 2021. A total of 336 suspected measles cases from the study population were analyzed for IgM antibodies using Enzyme-Linked Immunosorbent Assay (ELISA). Throat swabs were randomly collected from a subset of positive cases for molecular analysis. Phylogenetic analysis of MeV isolates was performed using the neighbor-joining method. The vaccination status of individuals was also recorded. RESULTS: Among the suspected participants, 61.0% (205/336) were ELISA positive for IgM antibodies, with a higher prevalence in males (64.17%) compared to females (57.04%). The majority of cases (36.0%) were observed in infants and toddlers, consistent with previous reports. The majority of IgM-positive cases (71.7%) had not received any dose of measles vaccine, highlighting gaps in vaccine coverage and the need for improved immunization programs. Genetic analysis revealed that all MeV isolates belonged to the B3 genotype, with minor genetic variations from previously reported variants in the region. CONCLUSION: This study provides valuable insights into the genetic epidemiology of the MeV in KPK, Pakistan. The high incidence of measles infection among unvaccinated individuals highlights the urgency of raising awareness about vaccine importance and strengthening routine immunization programs.
Asunto(s)
Anticuerpos Antivirales , Ensayo de Inmunoadsorción Enzimática , Genotipo , Inmunoglobulina M , Virus del Sarampión , Sarampión , Filogenia , Humanos , Virus del Sarampión/genética , Virus del Sarampión/inmunología , Virus del Sarampión/aislamiento & purificación , Virus del Sarampión/clasificación , Sarampión/epidemiología , Sarampión/virología , Femenino , Masculino , Pakistán/epidemiología , Estudios Transversales , Lactante , Preescolar , Anticuerpos Antivirales/sangre , Inmunoglobulina M/sangre , Niño , Adolescente , Adulto , Vacuna Antisarampión/inmunología , Epidemiología Molecular , Adulto Joven , Prevalencia , Estudios Seroepidemiológicos , Persona de Mediana EdadRESUMEN
BACKGROUND: Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease of the CNS. An intrathecal IgM synthesis is associated with a more rapid progression of MS and the intrathecal immune response to measles -, rubella -and varicella zoster virus (MRZR) which, if present, increases the likelihood of a diagnosis of MS in adults. OBJECTIVE: To evaluate the frequency of an intrathecal IgM synthesis and MRZR in children with MS. MethodsChildren with MS and a data set including clinical and treatment history, MRI at onset, in addition to a CSF analysis, and determination of antibody index (AI) of measles, rubella, and zoster antibodies, were eligible. The presence of an intrathecal IgM synthesis and/or a positive MRZ reaction were compared to biomarkers of a more progressive disease course. RESULTS: In 75 children with MS, OCBs were present in 93.3 %). 49,2 % experienced their first relapse within 6 months. 50.7 % had a total lesion load of more than 10 lesions in the first brain MRI. Spinal lesions were identified in 64 %. 23.5 % had a positive MRZR and 40.3 % an intrathecal IgM synthesis. No significant associations were detected between the presence of an intrathecal IgM synthesis and MRZR and parameters including the relapse rate in the first two years. CONCLUSION: An intrathecal IgM synthesis and a positive MRZR are found in a subset of MS children but are not associated with markers associated with a poor prognosis.
Asunto(s)
Inmunoglobulina M , Imagen por Resonancia Magnética , Esclerosis Múltiple , Humanos , Masculino , Inmunoglobulina M/líquido cefalorraquídeo , Niño , Femenino , Esclerosis Múltiple/diagnóstico por imagen , Esclerosis Múltiple/inmunología , Esclerosis Múltiple/líquido cefalorraquídeo , Adolescente , Herpesvirus Humano 3/inmunología , Anticuerpos Antivirales/líquido cefalorraquídeo , Anticuerpos Antivirales/sangre , Preescolar , Virus del Sarampión/inmunología , Virus de la Rubéola/inmunología , Progresión de la Enfermedad , Encéfalo/diagnóstico por imagen , Biomarcadores/líquido cefalorraquídeoRESUMEN
In the early COVID-19 pandemic with urgent need for countermeasures, we aimed at developing a replicating viral vaccine using the highly efficacious measles vaccine as vector, a promising technology with prior clinical proof of concept. Building on our successful pre-clinical development of a measles virus (MV)-based vaccine candidate against the related SARS-CoV, we evaluated several recombinant MV expressing codon-optimized SARS-CoV-2 spike glycoprotein. Candidate V591 expressing a prefusion-stabilized spike through introduction of two proline residues in HR1 hinge loop, together with deleted S1/S2 furin cleavage site and additional inactivation of the endoplasmic reticulum retrieval signal, was the most potent in eliciting neutralizing antibodies in mice. After single immunization, V591 induced similar neutralization titers as observed in sera of convalescent patients. The cellular immune response was confirmed to be Th1 skewed. V591 conferred long-lasting protection against SARS-CoV-2 challenge in a murine model with marked decrease in viral RNA load, absence of detectable infectious virus loads, and reduced lesions in the lungs. V591 was furthermore efficacious in an established non-human primate model of disease (see companion article [S. Nambulli, N. Escriou, L. J. Rennick, M. J. Demers, N. L. Tilston-Lunel et al., J Virol 98:e01762-23, 2024, https://doi.org/10.1128/jvi.01762-23]). Thus, V591 was taken forward into phase I/II clinical trials in August 2020. Unexpected low immunogenicity in humans (O. Launay, C. Artaud, M. Lachâtre, M. Ait-Ahmed, J. Klein et al., eBioMedicine 75:103810, 2022, https://doi.org/10.1016/j.ebiom.2021.103810) revealed that the underlying mechanisms for resistance or sensitivity to pre-existing anti-measles immunity are not yet understood. Different hypotheses are discussed here, which will be important to investigate for further development of the measles-vectored vaccine platform.IMPORTANCESARS-CoV-2 emerged at the end of 2019 and rapidly spread worldwide causing the COVID-19 pandemic that urgently called for vaccines. We developed a vaccine candidate using the highly efficacious measles vaccine as vector, a technology which has proved highly promising in clinical trials for other pathogens. We report here and in the companion article by Nambulli et al. (J Virol 98:e01762-23, 2024, https://doi.org/10.1128/jvi.01762-23) the design, selection, and preclinical efficacy of the V591 vaccine candidate that was moved into clinical development in August 2020, 7 months after the identification of SARS-CoV-2 in Wuhan. These unique in-human trials of a measles vector-based COVID-19 vaccine revealed insufficient immunogenicity, which may be the consequence of previous exposure to the pediatric measles vaccine. The three studies together in mice, primates, and humans provide a unique insight into the measles-vectored vaccine platform, raising potential limitations of surrogate preclinical models and calling for further refinement of the platform.